Furthermore, the identification of residual activity mutations in typical NPS patients suggests that the manifestation or absence of extrarenal symptoms may not solely rely on the transcriptional activity of the LMX1B gene.[5]. This evidence concerns the gene LMX1B and nail-patella syndrome.